Pipelinepharma was founded in 2012 by pharmaceutical industry executive Mindaugas Zagorskis (Founder and CEO) and technology executive Gediminas Vedrickas (Co-founder and CTO). The company operates exclusively as a business-to-business platform and does not serve individual consumers. The website does not state a headquarters address. The team and contact details point to Lithuania, but this is an inference rather than a stated fact.

The platform brings together sellers (developers, CTD dossier owners, and manufacturers of finished dosage form products) and buyers (pharmaceutical companies, distributors, and pharmacy chains). It supports several deal types: licensing and supply, technology transfer, distribution, special importation, contract manufacturing transfers, dossier co-development, and dossier or marketing authorisation divestments. Dedicated business development staff oversee transactions, and the company reports coverage across five continents and more than 40 markets. Deals are concluded directly between buyer and seller, and Pipelinepharma states that no brokerage fees apply. Revenue comes from buyer subscription plans and seller listing fees.

The company reports more than 103,600 finished dosage formulation products listed across over 100 countries of production, more than 2,000 dossier owners and CDMOs, and a reply rate above 90%. It cites more than 10,000 registered companies and names Macleods, Medochemie, Genepharm, Aristo, Rafarm, and Biofarm among its clients. Its investors include Practica Capital, Iron Wolf, Rockstart, and Kilo Health. The leadership team brings experience from Organon, Pfizer, PharmaSwiss, GSK, Ewopharma, and Allergan.

Key Products and Services

CTD Dossier Marketplace

• Searchable database of CTD dossiers across generics (96,600+ products), innovative products (270+), biosimilars (390+), medical devices (690+), and nutraceuticals (5,600+)
• Filters by GMP approval status, country of origin, dossier type, and dossier status
• Direct requests for quotation and manufacturer connections, with progress tracking on the platform

Pipeline Intelligence

• Tools to stress-test portfolios, assess market saturation, and identify portfolio gaps before R&D, market expansion, or commercial investment decisions
• Marketing Authorisations Database covering multiple national registers
• Active Pharmaceutical Ingredient database

Sourcing and Partnering Services

• Product finder and CMO/CDMO finder for BD, in-licensing, and sourcing teams
• Partner search (paid service) and a free product listing option for sellers
• Premium sourcing support and dedicated business development oversight of transactions

Advisory and Asset Services

• Advisory services for licensing, portfolio building, and re-risking
• Assets-for-sale listings covering dossier and MA divestments

Pipelinepharma occupies a distinct position in pharmaceutical business development as a specialised dossier-centric marketplace, where generalist B2B directories cover pharma only partially. Its core asset is a large, curated CTD dossier database, which lets buyers screen products by regulatory readiness and manufacturing status before approaching suppliers. Targeting generics, biosimilars, and value-added products, it serves a segment where partnering and in-licensing activity is high and supplier discovery is fragmented. The no-brokerage, direct-negotiation model and the pairing of pipeline intelligence with a sourcing engine help reduce time-to-contract for buyers. The self-reported metrics (dossier counts, reply rate, client numbers) are company claims and have not been independently verified.